Gossamer Bio reacquires worldwide seralutinib rights from Chiesi ahead of NDA submission
Gossamer Bio plans a September seralutinib NDA after FDA talks as Chiesi rights, cash pressure and Phase 3 risk reshape the case.
Pharma & Biotech
Pharma & Biotech
Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension
Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.